Document:

EX-4.2

 Exhibit 4.2 
 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS
SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS IS AVAILABLE WITH RESPECT THERETO. 

PREFERRED STOCK PURCHASE WARRANT 
  

			
	Warrant
No.                                	  	Number of Shares: a maximum of 200,000
		  	 Series A Preferred Stock
 Subject to determination as set for the below

 FOUNDATION MEDICINE, INC. 

Effective as of November 1, 2010 
 Void after November 1, 2018, or earlier in accordance with 

Section 7 of this Warrant 
 1. Issuance. This Preferred Stock Purchase Warrant (the “Warrant”) is issued to LIGHTHOUSE CAPITAL PARTNERS VI, L.P. by
FOUNDATION MEDICINE, INC., a Delaware corporation (hereinafter with its successors called the “Company”) in connection with that certain Loan and Security Agreement No. 1881
dated November 1, 2010 between the Company and Lighthouse Capital Partners VI, L.P. (the “Loan Agreement”). Capitalized terms not defined herein shall have the meaning as set forth in the Loan Agreement. 

2. Purchase Price; Number of Shares. 
 (a) The registered holder of this Warrant (the “Holder”), is entitled upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the principal
office of the Company, to purchase from the Company, at a price per share of $1.00 (the “Purchase Price”), up to a maximum of 200,000 fully paid and nonassessable shares of the Company’s Series A Preferred Stock, $0.0001 par
value (the “Preferred Stock”). Commencing on the date hereof, 100,000 (the “Exercise Quantity”) of shares of Preferred Stock are immediately available for purchase hereunder. 

(b) On the Commitment Termination Date or such earlier termination of this Warrant in accordance with the terms hereof, the
Exercise Quantity shall automatically be increased by such additional number of shares as is equal to (A) 2% of the amount of Aggregate Advances funded under the Loan Agreement, if any, divided by (B) the Purchase Price. 

In addition to other terms which may be defined herein, the following terms, as used in this Warrant, shall have the following meanings: 

 

	 	(i)	“Aggregate Advances” means the aggregate original dollar amount of Advances made under the Loan Agreement, whether such Advances are outstanding or
prepaid, at the time of any scheduled adjustment to the Exercise Quantity. 

 Until such time as this Warrant is exercised in full
or expires, the Purchase Price and the securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter provided. The person or persons in whose name or names any certificate representing shares of Preferred Stock is issued
hereunder shall be deemed to have become the holder of record of the shares represented thereby as at the close of business on the date this Warrant is exercised with respect to such shares, whether or not the transfer books of the Company shall be
closed. 

  
 1. 

 3. Payment of Purchase Price. The Purchase Price may be paid (i) in cash or by
check, (ii) by the surrender by the Holder to the Company of any promissory notes or other obligations issued by the Company to the Holder, with all such notes and obligations so surrendered being credited against the Purchase Price in an
amount equal to the principal amount thereof plus accrued interest to the date of surrender, or (iii) by any combination of the foregoing. 
 4. Net Issue Election. The Holder may elect to receive, without the payment by the Holder of any additional consideration, shares of Preferred Stock equal to the value of this Warrant or any
portion hereof by the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto duly executed, at the principal office of the Company. Thereupon, the Company shall issue to the Holder such number of
fully paid and nonassessable shares of Preferred Stock as is computed using the following formula: 

X= Y(A-B) 
   A 
  

					
	        where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Holder pursuant to this Section 4.
			
		  	Y =	  	the number of shares of Preferred Stock covered by this Warrant in respect of which the net issue election is made pursuant to this Section 4.
			
		  	A =	  	the Fair Market Value (defined below) of one share of Preferred Stock, as determined at the time the net issue election is made pursuant to this
Section 4.
			
		  	B =	  	the Purchase Price in effect under this Warrant at the time the net issue election is made pursuant to this Section 4.

 “Fair Market Value” of a share of Preferred Stock (or fully paid and nonassessable
shares of the Company’s common stock, $0.0001 par value (the “Common Stock”) if the Preferred Stock has been automatically converted into Common Stock) as of the date that the net issue election is made (the
“Determination Date”) shall mean: 
 (i) If the net issue election is made in connection with and
contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a Registration Statement under the 1933 Act (a “Public Offering”), and if the Company’s Registration
Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect
to such offering multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then convertible. 
 (ii) If the net issue election is not made in connection with and contingent upon a Public Offering, then as follows: 
 (a) If traded on a securities exchange or NASDAQ market or system, the fair market value of the Common Stock shall be deemed to be the average of the closing or last reported sale prices of the
Common Stock on such exchange or market over the five day period ending five trading days prior to the Determination Date, and the fair market value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock multiplied
by the number of shares of Common Stock into which each share of Preferred Stock is then convertible; 
 (b) If
otherwise traded in an over-the-counter market, the fair market value of the Common Stock shall be deemed to be the average of the closing ask prices of the Common Stock over the five day period ending five trading days prior to the Determination
Date, and the fair market value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then convertible; and 

(c) If there is no public market for the Common Stock, then fair market value shall be determined in good faith by the
Company’s Board of Directors. 

  
 2. 

 5. Partial Exercise. This Warrant may be exercised in part at any time, and the
Holder shall be entitled to receive a new warrant, which shall be dated as of the date of this Warrant, covering the number of shares in respect of which this Warrant shall not have been exercised. 

6. Fractional Shares. In no event shall any fractional share of Preferred Stock be issued upon any exercise of this Warrant. If,
upon exercise of this Warrant in its entirety, the Holder would, except as provided in this Section 6, be entitled to receive a fractional share of Preferred Stock, then the Company shall pay the Holder an amount in cash equal to such
fraction of a share of Preferred Stock at such time. 
 7. Expiration Date; Automatic Exercise. This Warrant shall expire
at the earliest to occur of (the “Expiration Date”) (i) at the close of business on November 1, 2018; (ii) the second anniversary date of the effectiveness of the Company’s initial Public Offering; on the NASDAQ
or other stock exchange in the United States; or (iii) the effective date of a Merger (as defined below), and shall be void thereafter. 
 Notwithstanding the term of this Warrant fixed pursuant to this Section 7, and provided Holder has received advance written notice of at least twenty (20) days and has not earlier
exercised this Warrant, and provided this Warrant has not been assumed by the successor entity (or parent thereof), upon the consummation of a Merger (as defined below), this Warrant shall automatically be exercised pursuant to Section 4
hereof, without any action by Holder. “Merger” means: (i) a sale of all or substantially all of the Company’s assets to an Unaffiliated Entity (as defined below), or (ii) the merger, consolidation or acquisition of
the Company with, into or by an Unaffiliated Entity (other than a merger or consolidation for the principle purpose of changing the domicile of the Company or a bona fide round of preferred stock equity financing), that results in the transfer of
fifty percent (50%) or more of the outstanding voting power of the Company. “Unaffiliated Entity” means any entity that is owned or controlled by parties who own less than twenty percent (20%) of the combined voting power
of the voting securities of the Company immediately prior to such merger, consolidation or acquisition. Notwithstanding the foregoing, in the event that any outstanding warrants to purchase equity securities of the Company are assumed by the
successor entity of a Merger (or parent thereof), this Warrant shall also be similarly assumed. The Company agrees to promptly give the Holder written notice of any proposed Merger and written notice of termination of any proposed Merger.
Notwithstanding anything to the contrary in this Warrant, the Holder may rescind any exercise of its purchase rights after a notice of termination of the proposed Merger if the exercise of this Warrant occurred after the Company notified the Holder
that the Merger was proposed or if the exercise was otherwise precipitated by such proposed Merger, provided, however that such rescission right must be exercised within thirty (30) days of receipt of such written notice of termination of the
proposed Merger. In the event of such rescission, this Warrant will continue to be exercisable on the same terms and conditions. 
 8. Reserved Shares; Valid Issuance. The Company covenants that it will at all times from and after the date hereof reserve and keep available such number of its authorized shares of Preferred Stock
and Common Stock free from all preemptive or similar rights therein, as will be sufficient to permit, respectively, the exercise of this Warrant in full and the conversion into shares of Common Stock of all shares of Preferred Stock receivable upon
such exercise. The Company further covenants that such shares as may be issued pursuant to such exercise and/or conversion will, upon issuance, be duly and validly issued, fully paid and nonassessable and free from all taxes, liens and charges with
respect to the issuance thereof. 
 9. Stock Splits and Dividends. If after the date hereof the Company shall subdivide
the Preferred Stock, by split-up or otherwise, or combine the Preferred Stock, or issue additional shares of Preferred Stock in payment of a stock dividend on the Preferred Stock, the number of shares of Preferred Stock issuable on the exercise of
this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Purchase Price shall forthwith be proportionately decreased in the case of a
subdivision or stock dividend, or proportionately increased in the case of a combination. 
 10. Adjustments for Diluting
Issuances. The other antidilution rights applicable to the Preferred Stock of the Company are set forth in the Amended and Restated Certificate of Incorporation, as amended from time to time (the “Articles”), a true and complete
copy in its current form which is attached hereto as Exhibit A. Until full exercise or expiration of this Warrant, such rights shall not be restated, amended or modified in any manner which affects the Holder differently than the
holders of Preferred Stock without such Holder’s prior written consent, provided, however, that nothing herein shall be deemed to restrict the restatement, amendment or modification of the Articles, in accordance with the provisions of the
Articles, in a manner that affects equally all holders of Preferred Stock. The Company shall promptly provide the Holder hereof with any restatement, amendment or modification to the Articles promptly after the same has been made. 

  
 3. 

 11. Mergers and Reclassifications. Subject to the expiration provisions of
Section 7, if after the date hereof the Company shall enter into any Reorganization (as hereinafter defined), then, as a condition of such Reorganization, lawful provisions shall be made, and duly executed documents evidencing the same
from the Company or its successor shall be delivered to the Holder, so that the Holder shall thereafter have the right to purchase, at a total price not to exceed that payable upon the exercise of this Warrant in full, the kind and amount of shares
of stock and other securities and property receivable upon such Reorganization by a holder of the number of shares of Preferred Stock which might have been purchased by the Holder immediately prior to such Reorganization, and in any such case
appropriate provisions shall be made with respect to the rights and interest of the Holder to the end that the provisions hereof (including without limitation, provisions for the adjustment of the Purchase Price and the number of shares issuable
hereunder and the provisions relating to the net issue election) shall thereafter be applicable in relation to any shares of stock or other securities and property thereafter deliverable upon exercise hereof. For the purposes of this
Section 11, the term “Reorganization” shall include without limitation any reclassification, capital reorganization or change of the Preferred Stock (other than a Merger as defined in Section 7 or as a result
of a subdivision, combination or stock dividend provided for in Section 9 hereof). 
 12. Certificate of
Adjustment. Whenever the Purchase Price is adjusted, as herein provided, the Company shall promptly deliver to the Holder a certificate of the Company’s chief financial officer setting forth the Purchase Price after such adjustment and
setting forth a brief statement of the facts requiring such adjustment. 
 13. Notices of Record Date, Etc. In the event
of: 
 (a) any taking by the Company of a record of the holders of any class of securities for the purpose of determining
the holders thereof who are entitled to receive any dividend or other distribution, or any right to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any class or any other securities or property, or to receive
any other right; 
 (b) any reclassification of the capital stock of the Company, capital reorganization of the Company,
consolidation or merger involving the Company, or sale or conveyance of all or substantially all of its assets; or 
 (c)
any voluntary or involuntary dissolution, liquidation or winding-up of the Company; 
 then in each such event the Company will provide or
cause to be provided to the Holder a written notice thereof. Such notice shall be provided at least twenty (20) business days prior to the date specified in such notice on which any such action is to be taken. 

14. Representations, Warranties and Covenants. This Warrant is issued and delivered by the Company and accepted by each Holder on
the basis of the following representations, warranties and covenants made by the Company: 
 (a) The Company has all
necessary authority to issue, execute and deliver this Warrant and to perform its obligations hereunder. This Warrant has been duly authorized issued, executed and delivered by the Company and is the valid and binding obligation of the Company,
enforceable in accordance with its terms. 
 (b) The shares of Preferred Stock issuable upon the exercise of this Warrant
have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable. 
 (c) The issuance, execution and delivery of this Warrant do not, and the issuance of the shares of Preferred Stock upon the exercise of this Warrant in accordance with the terms hereof will not,
(i) violate or contravene the Company’s Articles or by-laws, or any law, statute, regulation, rule, judgment or order applicable to the Company, (ii) violate, contravene or result in a breach or default under any contract, agreement
or instrument to which the Company is a party or by which the Company or any of its assets are bound or (iii) require the consent or approval of or the filing of any notice or registration with any person or entity. 

  
 4. 

 (d) As long as this Warrant is, or any shares of Preferred Stock issued upon exercise
of this Warrant or any shares of Common Stock issued upon conversion of such shares of Preferred Stock are, issued and outstanding, the Company will provide to the Holder (i) as soon as practicable, but in any event within 190 days after the
end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a statement of cash flows for such year, plus, where
applicable, comparisons to the annual budget and operating plan approved by the Board of Directors; such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles in the United States
(“GAAP”), and audited and certified by an independent public accounting firm of nationally or regionally recognized standing selected by the Board of Directors; and (ii) as soon as practicable, but in any event within 30 days after
the end of each of the first three quarters of each fiscal year, an unaudited profit or loss statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, plus, where applicable,
quarterly comparisons to the annual budget and operating plan approved by the Board of Directors; such unaudited financial statements to be prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the
exception of footnotes that may be required by GAAP) and that fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment. 

(e) As of the date hereof, the authorized capital stock of the Company consists of (i) 40,200,000 shares of Common Stock, of
which (x) 17, 350,000 shares are issued and outstanding, (y) 323,500 shares have been approved and authorized for sale and issuance by the Company (and which, upon issuance, shall be subject to the terms and conditions of applicable
restricted stock agreements, and (z) and 200,000 shares are reserved for issuance upon the exercise of this Warrant with respect to Common Stock and the conversion of the Preferred Stock into Common Stock if this Warrant is exercised with
respect to Preferred Stock, and (ii) 25,200,000 shares of Series A Preferred Stock, of which 7,000,000 shares are issued and outstanding. Attached hereto as Exhibit B is a capitalization table summarizing the capitalization
of the Company as of November 1, 2010. Once per calendar quarter and upon request from Holder, the Company will provide Holder with a current capitalization table indicating changes, if any, to the number of outstanding shares of common stock
and preferred stock. 
 15. Registration Rights. The Company grants to the Holder all the rights of a “Holder”
under Section 2.2 of the Company’s Investors’ Rights Agreement dated as of March 30, 2010 and shall treat the shares of Common Stock issuable upon conversion of the shares of Preferred Stock issuable upon exercise of this Warrant
as “Registrable Securities,” as described therein. 
 16. Amendment. The terms of this Warrant may be
amended, modified or waived only with the written consent of the Holder and the Company. 
 17. Representations, Warranties
and Covenants of the Holder. This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Holder, which by its execution hereof the Holder hereby confirms: 

(a) Investment Purpose. The right to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the Holder’s
rights contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
 (b) Accredited Investor. Holder is an “accredited investor” within the meaning of
the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (c) Private Issue. The Holder
understands (i) that the Preferred Stock issuable upon exercise of the Holder’s rights contained herein is not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated
by this Warrant will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 17. 

(d) Financial Risk. The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment and has the ability to bear the economic risks of its investment. 

  
 5. 

 (e) Information. The Holder acknowledges that it has been afforded the opportunity to
meet with the management of the Company and to ask question of, and receive answers from, such management about the business and affairs of the Company and concerning the terms and conditions of the offering of this Warrant, and to obtain any
additional information, necessary to verify the accuracy of the information otherwise obtained by or furnished to the Holder in connection with the offering of this Warrant. The Holder agrees that the Company has furnished to the Holder all
information which the Holder considered necessary t form a decision concerning the purchase of this Warrant, and no request to the Company by the Holder for information of any kind about the Company has been refused or denied by the Company or
remains unfulfilled as of the date hereof. 
 (f) Legends. The Holder acknowledges that certificates for securities
purchased under this Warrant shall bear the following legend or a legend substantially similar thereto: 
 THE SHARES OF [SERIES
A PREFERRED STOCK/COMMON STOCK] 
 REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT 
 BE SOLD OR TRANSFERRED UNLESS THE REGISTRATION PROVISIONS 
 OF THE SAID ACT HAVE
BEEN COMPLIED WITH OR UNLESS THE 
 COMPANY HAS RECEIVED AN OPINION OF COUNSEL IN FORM AND 

SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE 
 EFFECT THAT COMPLIANCE WITH SUCH PROVISIONS IS NOT REQUIRED. 
 18. Notices,
Transfers, Etc. 
 (a) Any notice or written communication required or permitted to be given to the Holder may be
given by certified mail or delivered to the Holder at the address most recently provided by the Holder to the Company. 
 (b)
Subject to compliance with applicable federal and state securities laws, this Warrant may be transferred by the Holder with respect to any or all of the shares purchasable hereunder. Upon surrender of this Warrant to the Company, together with
the assignment notice annexed hereto duly executed, for transfer of this Warrant as an entirety by the Holder, the Company shall issue a new warrant of the same denomination to the assignee. Upon surrender of this Warrant to the Company, together
with the assignment hereof properly endorsed, by the Holder for transfer with respect to a portion of the shares of Preferred Stock purchasable hereunder, the Company shall issue a new warrant to the assignee, in such denomination as shall be
requested by the Holder hereof, and shall issue to such Holder a new warrant covering the number of shares in respect of which this Warrant shall not have been transferred. 
 (c) In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall issue a new warrant of like tenor and denomination and deliver the same (i) in exchange and
substitution for and upon surrender and cancellation of any mutilated Warrant, or (ii) in lieu of any Warrant lost, stolen or destroyed, upon receipt of an affidavit of the Holder or other evidence reasonably satisfactory to the Company of the
loss, theft or destruction of such Warrant 
 19. No Impairment. The Company will not, without the prior written consent
of the Holder, by amendment of its Articles or through any reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets, dissolution, liquidation, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance of performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the Holder. 
 20. Governing Law. The provisions and terms of this Warrant shall be governed by and
construed in accordance with the internal laws of the State of Delaware without giving effect to its principles regarding conflicts of laws. 
 21. Successors and Assigns. This Warrant shall be binding upon the Company’s successors and assigns and shall inure to the benefit of the Holder’s successors, legal representatives and
permitted assigns. 
 22. Business Days. If the last or appointed day for the taking of any action required or the
expiration of any rights granted herein shall be a Saturday or Sunday or a legal holiday in Massachusetts, then such action may be taken or right may be exercised on the next succeeding day which is not a Saturday or Sunday or such a legal holiday.

  
 6. 

 23. Qualifying Public Offering. If the Company shall effect a firm commitment
underwritten Public Offering of shares of Common Stock which results in the conversion of the Preferred Stock into Common Stock pursuant to the Company’s Articles in effect immediately prior to such offering, then, effective upon such
conversion, this Warrant shall change from the right to purchase shares of Preferred Stock to the right to purchase shares of Common Stock, and the Holder shall thereupon have the right to purchase, at a total price equal to that payable upon the
exercise of this Warrant in full, the number of shares of Common Stock which would have been receivable by the Holder upon the exercise of this Warrant for shares of Preferred Stock immediately prior to such conversion of such shares of Preferred
Stock into shares of Common Stock, and in such event appropriate provisions shall be made with respect to the rights and interest of the Holder to the end that the provisions hereof (including, without limitation, the provisions for the adjustment
of the Purchase Price and of the number of shares purchasable upon exercise of this Warrant and the provisions relating to the net issue election) shall thereafter be applicable to any shares of Common Stock deliverable upon the exercise hereof. In
connection with any such Public Offering, the Holder shall also agree to execute a lock-up agreement if reasonably requested by the Company and the managing underwriter of such offering. 

24. Status of Holder. Except as may be set forth herein or to the extent the Holder may be entitled to certain rights pursuant to
other agreements with the Company or the Company’s stockholders, this Warrant neither entitles the Holder to any rights, voting or otherwise, nor subjects the Holder to any responsibilities or liabilities, as a stockholder of the Company.

 25. Value. The Company and the Holder agree that the value of this Warrant on the date of grant is $100.

  

			
	FOUNDATION MEDICINE, INC.
		
	By:	 	/s/ Alexis Borisy
	Name:	 	Alexis Borisy
	Title:	 	CEO

  
 7. 

 Subscription 
 To:
                                         
            
 Date:
                                         
        
 The undersigned hereby subscribes for
             shares of Preferred Stock covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise indicated below:

  

	
	  
	Signature
	  
	Name for Registration
	  
	Mailing Address

  
 1. 

 Net Issue Election Notice 

 

			
	To:                             
                                       	  	Date:                          
          

 The undersigned hereby elects under Section 4 to surrender the right to purchase shares of Preferred Stock
pursuant to this Warrant. The certificate(s) for such shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below: 

 

	
	  
	Signature
	  
	Name for Registration
	  
	Mailing Address

  
 1. 

 Assignment 
 For value received
                                         
                                         
                           hereby sells, assigns and transfers unto 

 
  
  

 
 [Please print or typewrite name and address of
Assignee] 
  
  
 the within Warrant, and does hereby irrevocably constitute and appoint
                                        
its attorney to transfer the within Warrant on the books of the within named Company with full power of substitution on the premises. 
 Dated:
                                        

  

	
	  
	Signature
	  
	Name for Registration
	 
	In the Presence of:
	  

  
 1.EX-4.3

 EXHIBIT 4.3 

 
  
 FOUNDATION MEDICINE, INC. 
 SECOND AMENDED AND RESTATED INVESTORS’
RIGHTS AGREEMENT 
 June 20, 2013 

 
  

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 Section 1 Definitions
	  	 	1	  
	 1.1
	  	Certain Definitions	  	 	1	  
	 Section 2 Registration Rights
	  	 	4	  
	 2.1
	  	Demand Registration	  	 	4	  
	 2.2
	  	Company Registration	  	 	6	  
	 2.3
	  	Registration on Form S-3	  	 	7	  
	 2.4
	  	Expenses of Registration	  	 	8	  
	 2.5
	  	Registration Procedures	  	 	9	  
	 2.6
	  	Indemnification	  	 	11	  
	 2.7
	  	Information by Holder	  	 	13	  
	 2.8
	  	Restrictions on Transfer	  	 	13	  
	 2.9
	  	Rule 144 Reporting	  	 	15	  
	 2.10
	  	Market Stand-Off Agreement	  	 	16	  
	 2.11
	  	Delay of Registration	  	 	16	  
	 2.12
	  	Transfer or Assignment of Registration Rights	  	 	16	  
	 2.13
	  	Limitations on Subsequent Registration Rights	  	 	17	  
	 2.14
	  	Termination of Registration Rights	  	 	17	  
	 Section 3 Covenants of the Company
	  	 	17	  
	 3.1
	  	Basic Financial Information	  	 	17	  
	 3.2
	  	Inspection Rights	  	 	18	  
	 3.3
	  	Confidentiality	  	 	18	  
	 3.4
	  	Vesting	  	 	19	  
	 3.5
	  	D&O Insurance	  	 	19	  
	 3.6
	  	Certain Approval Requirements	  	 	20	  
	 3.7
	  	Non-Disclosure, Assignment of Inventions and Non-Competition and Non-Solicitation Agreements	  	 	21	  
	 3.8
	  	Termination of Covenants	  	 	21	  
	 Section 4 Right of First Refusal
	  	 	21	  
	 4.1
	  	Right of Refusal of the Investors	  	 	21	  
	 Section 5 Miscellaneous
	  	 	23	  
	 5.1
	  	Additional investors; Permitted Transferees	  	 	23	  
	 5.2
	  	Amendment; Waiver	  	 	23	  

  
 i 

							
	 5.3
	  	Notices	  	 	24	  
	 5.4
	  	Governing Law	  	 	24	  
	 5.5
	  	Successors and Assigns	  	 	24	  
	 5.6
	  	Entire Agreement	  	 	24	  
	 5.7
	  	Delays or Omissions	  	 	25	  
	 5.8
	  	Severability	  	 	25	  
	 5.9
	  	Titles and Subtitles	  	 	25	  
	 5.10
	  	Counterparts	  	 	25	  
	 5.11
	  	Telecopy Execution and Delivery	  	 	25	  
	 5.12
	  	Further Assurances	  	 	26	  
	 5.13
	  	Aggregation of Stock	  	 	26	  

  
 ii 

 FOUNDATION MEDICINE, INC. 

SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This Second Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of June 20, 2013,
by and among Foundation Medicine, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the
“Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1. 
 RECITALS 
 WHEREAS: The Company and the Investors have previously
entered into that certain Amended and Restated Investors’ Rights Agreement dated as of September 10, 2012 (the “Prior Agreement”) and desire to amend and restate the Prior Agreement and to accept the rights created
pursuant hereto in lieu of the rights created under the Prior Agreement. 
 NOW, THEREFORE: In consideration of the
mutual promises and covenants set forth herein, and other consideration, the receipt of and adequacy of which is hereby acknowledged, the parties hereto further agree as follows: 

SECTION 1 
 DEFINITIONS 
 1.1 Certain Definitions. As used in this
Agreement, the following terms shall have the meanings set forth below: 
 (a) “Affiliated Fund” shall have the
meaning set forth in Section 2.8(a)(iii) hereof. 
 (b) “Commission” shall mean the U.S. Securities and
Exchange Commission or any other federal agency at the time administering the Securities Act. 
 (c) “Common
Stock” shall mean the Common Stock, par value $0.0001 per share of the Company. 
 (d) “Conversion
Stock” shall mean the shares of Common Stock issued upon conversion of the Preferred Stock. 
 (e) “Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(f) “Exempted Registration” shall mean a registration relating solely to employee benefit plans, a registration relating
to the offer and sale of non-convertible debt securities, a registration relating to a corporate reorganization or other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales. 

 (g) “Holder” shall mean (i) any Investor that holds Registrable
Securities and (ii) any holder of Registrable Securities to whom the registration rights conferred by this Agreement have been duly and validly transferred in accordance with Section 2.12 of this Agreement; provided, however,
that for purposes of this Agreement, a record holder of shares of Preferred Stock convertible into such Registrable Securities shall be deemed to be the Holder of such Registrable Securities; provided, further, that the Company shall
in no event be obligated to register shares of Preferred Stock, and that Holders of Registrable Securities will not be required to convert their shares of Preferred Stock into Common Stock in order to exercise the registration rights granted
hereunder, until immediately before the closing of the offering to which the registration relates. 
 (h) “Indemnified
Party” shall have the meaning set forth in Section 2.6(c) hereof. 
 (i) “Indemnifying Party”
shall have the meaning set forth in Section 2.6(c) hereof. 
 (j) “Initial Public Offering” shall mean the
closing of the Company’s first firm commitment underwritten public offering of Common Stock registered under the Securities Act. 
 (k) “Initiating Holders” shall mean, collectively, Holders who properly initiate a registration request under this Agreement. 

(l) “Investors” shall mean the persons and entities listed on Schedule A hereto. 

(m) “New Securities” shall have the meaning set forth in Section 4.1(b) hereof. 

(n) “Preferred Stock” shall mean the Series A Preferred Stock and the Series B Preferred Stock. 

(o) “Preferred Stock Directors” shall mean representatives of the holders of shares of Preferred Stock on the
Company’s Board of Directors (the “Board of Directors”) elected in accordance with the Third Amended and Restated Stockholders’ Voting Agreement, by and among the Company and the other parties thereto dated as of
September 10, 2012, as it may be amended and/or restated from time to time. 
 (p) “Purchase Agreement”
shall mean that certain Series B Convertible Preferred Stock Purchase Agreement dated as of September 10, 2012, as amended, among the Company and the Investors listed on the Schedule of Investors thereto. 

(q) “Qualified Public Offering” shall have the meaning set forth in the Restated Certificate. 

  
 2 

 (r) “Registrable Securities” shall mean (i) shares of Common Stock
issuable or issued pursuant to the conversion of the Shares, (ii) shares of Common Stock issued or issuable (directly or indirectly) upon conversion of any capital stock of the Company owned or later acquired by the Investors, and
(iii) any shares of Common Stock issued as a dividend or other distribution with respect to or in exchange for or in replacement of the shares referenced in (i) or (ii) above; provided, however, that Registrable
Securities shall not include any shares of Common Stock described in clauses (i), (ii) or (iii) above (A) which have previously been registered, and sold to the public through a registration statement, (B) which have been sold in
a transaction exempt from the registration and prospectus delivery requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto were able to be removed upon the consummation of such sale or
(C) which have been sold in a private transaction in which the transferor’s rights under this Agreement are not validly assigned in accordance with this Agreement. 
 (s) The terms “register,” “registered” and “registration” shall refer to a registration effected by preparing and filing a registration statement in
compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement. 
 (t) “Registration Expenses” shall mean all expenses incurred by the Company in effecting any registration pursuant to this Agreement, including, without limitation, all registration,
qualification, and filing fees, printing expenses, accounting fees, escrow fees, fees and disbursements of counsel for the Company, fees and disbursements of one special counsel for the Holders (selected by a majority-in-interest of the Holders),
blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, fees and disbursements of other counsel for the Holders and the compensation of
regular employees of the Company, which shall be paid in any event by the Company. 
 (u) “Restated
Certificate” shall mean the Fifth Amended and Restated Certificate of Incorporation of the Company, as it may be amended and/or restated from time to time. 
 (v) “Restricted Securities” shall mean any Registrable Securities required to bear the first legend set forth in Section 2.8(b) hereof. 

(w) “Rule 144” shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be
amended from time to time, or any similar successor rule that may be promulgated by the Commission. 
 (x) “Rule
145” shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(y) “Securities Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the
rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (z) “Selling
Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Holder (other than the fees and disbursements of
one special counsel to the Holders included in Registration Expenses). 

  
 3 

 (aa) “Series A Preferred Stock” shall mean the shares of Series A
Convertible Preferred Stock, par value $0.0001 per share, of the Company. 
 (bb) “Series B Preferred Stock”
shall mean the shares of Series B Convertible Preferred Stock, par value $0.0001 per share, of the Company. 
 (cc)
“Shares” shall mean (i) the Series B Preferred Stock issued to the Investors pursuant to the terms of the Purchase Agreement, (ii) the Series A Preferred Stock held by the Investors as of the date hereof, and
(iii) any securities issued with respect to the foregoing upon any stock split, stock dividend, recapitalization, or similar event or upon any conversion. 
 (dd) “Super Board Approval” shall mean the approval of the Company’s Board of Directors, including the approval of at least seventy percent (70%) of the directors then in
office. 
 SECTION 2 
 REGISTRATION RIGHTS 
 2.1 Demand Registration. 

(a) Demand for Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall receive from
Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to at least twenty-five percent (25%) of the Registrable Securities (or a lesser amount if such offering shall have an
aggregate offering price to the public of not less than Five Million Dollars ($5,000,000)) (such request shall state the number of shares of Registrable Securities to be disposed of by such Initiating Holders), the Company will: 

(i) within ten (10) days give written notice of the proposed registration to all other Holders; and 

(ii) as soon as practicable, file and use its commercially reasonable efforts to effect such registration (including,
without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or other state securities laws, and appropriate compliance with the Securities Act) and to permit or facilitate the sale and distribution of
all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such request as are specified in a written request received by
the Company within twenty (20) days after such written notice from the Company is mailed; provided that the Company shall file the registration statement within sixty (60) days of the receipt of the request from the Initiating
Holders. 

  
 4 

 (b) Limitations on Demand Registration. The Company shall not be obligated to effect,
or to take any action to effect, any such registration pursuant to this Section 2.1: 
 (i) Prior to the
earlier of (a) five (5) years after the date of the Prior Agreement or (b) six (6) months following the closing of the Initial Public Offering; 

(ii) In any particular jurisdiction in which the Company would be required to execute a general consent to service of
process in effecting such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(iii) After the Company has initiated two (2) such registrations pursuant to this Section 2.1 (counting for
these purposes only registrations which have been declared or ordered effective and pursuant to which not less than all of the Registrable Securities that Holders have requested to be included in such registrations are actually included and sold in
such registrations); or 
 (iv) During the period starting with the date sixty (60) days prior to the
Company’s good faith estimate of the date of filing of, and ending on a date one hundred eighty (180) days after the effective date of, a Company-initiated registration; provided that the Company is actively employing, in good
faith, commercially reasonable efforts to cause such registration statement to become effective. 
 (c) Deferral. If
(i) in the good faith judgment of the Board of Directors, the filing of a registration statement covering the Registrable Securities would be materially detrimental to the Company and the Board of Directors concludes, as a result, that it is in
the best interests of the Company to defer the filing of such registration statement at such time, and (ii) the Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment
of the Board of Directors, it would be materially detrimental to the Company for such registration statement to be filed in the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration
statement, then (in addition to the limitations set forth in Section 2.l(b)(iv) above), the Company shall have the right to defer such filing for a period of not more than sixty (60) days after receipt of the request of the Initiating
Holders, and, provided further that the Company shall not defer its obligation in this manner more than once in any twelve (12) month period and provided further, the Company shall not register any securities for its
own account or that of any other stockholder during such sixty (60) day period other than an Exempted Registration. 
 (d)
Underwriting. If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.1
and the Company shall include such information in the written notice referred to in subsection 2.1(a)(i). In such event, the right of any Holder to include all or any portion of its Registrable Securities in a registration pursuant to this
Section 2.1 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities to the extent provided herein. If the Company shall request inclusion in any registration
pursuant to Section 2.1 of securities being sold for its own account, or if other persons shall request inclusion in any registration pursuant to Section 2.1, the Initiating Holders shall, on behalf of all Holders, offer to include such
securities in the underwriting and such offer shall be conditioned upon the participation of the Company or such other persons in such underwriting and the inclusion of the 

  
 5 

 
Company’s and such person’s other securities of the Company and their acceptance of the further applicable provisions of this Section 2 (including Section 2.10). The Company
shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or underwriters selected for such underwriting by
the Company and approved by Holders of at least two-thirds of the Registrable Securities to be registered. 
 Notwithstanding
any other provision of this Section 2.1, if the underwriters advise the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so
included shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. In no event shall
Registrable Securities be excluded from such registration unless all other stockholders’ securities (including securities for the account of the Company) have been first excluded. 

If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such
person shall be excluded therefrom by written notice from the Company, the underwriters or the Initiating Holders. The securities so excluded shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or
withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to be included in such registration was previously reduced as a result of marketing factors
pursuant to this Section 2.1(d), then the Company shall then offer to all Holders who have retained rights to include securities in the registration the right to include additional Registrable Securities in the registration in an aggregate
amount equal to the number of shares so withdrawn, with such shares to be allocated among such Holders requesting additional inclusion, as set forth above. 
 2.2 Company Registration. 
 (a) Company Registration. If the Company
shall determine to register any of its securities either for its own account or the account of a security holder or holders, other than a registration pursuant to Section 2.1 or 2.3 or an Exempted Registration: 

(i) within ten (10) days give written notice of the proposed registration to all Holders; and 

(ii) include in such registration (and any related qualification under blue sky laws or other compliance), except as set
forth in Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received by the Company within twenty (20) days
after such written notice from the Company is delivered. Such written request may specify all or a part of a Holder’s Registrable Securities. If a Holder decides not to include all of its Registrable Securities in any registration statement
thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to
offerings of its securities, all upon the terms and conditions set forth herein. 

  
 6 

 (b) Underwriting. If the registration of which the Company gives notice is for a
registered public offering involving an underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In such event, the right of any Holder to registration pursuant to this
Section 2.2(b) shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall (together with the Company and the other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an
underwriting agreement in customary form with the representative of the underwriter or underwriters selected by the Company. 

Notwithstanding any other provision of this Section 2.2, if the underwriters advise the Company in writing that marketing factors
require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) limit the number of Registrable Securities to be included in the registration and underwriting. In no event shall any
Registrable Securities be excluded from such registration and underwriting unless all other stockholders’ securities have been first excluded. In the event that the underwriters determine that less than all of the Registrable Securities
requested to be registered can be included in such registration and underwriting, then the Registrable Securities that are included in such registration and underwriting shall be apportioned pro rata among the selling Holders based on the number of
Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall the amount of securities of the selling Holders included in
the registration and underwriting be reduced below thirty percent (30%) of the total amount of securities included in such registration and underwriting. 
 If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such person shall also be excluded therefrom by written notice from the
Company or the underwriter. The securities so excluded shall also be withdrawn from such registration. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall be withdrawn from such registration. 

(c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it
under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 
 2.3 Registration on Form S-3. 
 (a) Request for Form S-3
Registration. If the Company is then qualified for the use of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 2 and subject to the conditions set forth in this Section 2.3, if the Company shall
receive from the Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration on Form S-3 or any similar short form registration statement with respect

  
 7 

 
to all or part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed of and the intended methods of disposition of such shares by
such Holder or Holders), the Company will take all such action with respect to such Registrable Securities as required by Section 2.1(a)(i) and (ii); provided, that in the case of a registration pursuant to this Section 2.3, the Company
shall file the registration statement within forty-five (45) days of the receipt of the request from the Initiating Holders. 
 (b) Limitations on Form S-3 Registration. The Company shall not be obligated to effect, or take any action to effect, any such registration pursuant to this Section 2.3: 

(i) In the circumstances described in either Sections 2.1(b)(ii) or 2.l(b)(iv); 

(ii) If the Initiating Holders, together with the holders of any other securities of the Company entitled to inclusion in
such registration, propose to sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less than Three Million Dollars ($3,000,000); or 

(iii) If, in a given twelve (12) month period, the Company has effected two (2) such registrations in such
period. 
 (c) Deferral. The provisions of Section 2.1(c) shall apply to any registration pursuant to this
Section 2.3. 
 (d) Underwriting. If the Initiating Holders requesting registration under this Section 2.3
intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of Sections 2.1(d) shall apply to such registration. Notwithstanding anything contained herein to the contrary, registrations
effected pursuant to this Section 2.3 shall not be counted as requests for registration or registrations effected pursuant to Section 2.1. 
 2.4 Expenses of Registration. All Registration Expenses incurred in connection with registrations pursuant to Sections 2.1, 2.2 and 2.3 hereof shall be borne by the Company; provided, however, that
the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently withdrawn at the request of the Holders of at least two-thirds of the
Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Sections 2.1 and 2.3 are no longer satisfied (in which case all participating Holders shall
bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the Holders of at least two-thirds of the Registrable Securities agree to forfeit their right to one demand
registration pursuant to Section 2.1(a); and provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Company
from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such
expenses and shall retain their rights pursuant to Section 2.1 or 2.3. All Selling Expenses shall be borne pro rata by the selling Holders based on the number of Registrable Securities requested to be so registered. 

  
 8 

 2.5 Registration Procedures. In the case of each registration effected by the Company
pursuant to Section 2, the Company will keep each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the Company will use its commercially reasonable efforts to: 

(a) Keep such registration effective for a period ending on the earlier of (1) the date which is one hundred twenty (120) days
from the effective date of the registration statement or (2) such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; provided, however, that (i) such one
hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such
registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable Commission rules, such one hundred twenty
(120) day period shall be extended for up to twelve (12) months, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in
connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection
(a) above; provided further that in connection with any registration on Form S-3 pursuant to Section 2.3 above, the Company agrees to timely file all reports required under the Exchange Act in order to maintain the right to
continue to use such Form S-3 and to maintain such registration in effect; 
 (c) Furnish such number of prospectuses, including
any preliminary prospectuses, and other documents incident thereto, including any amendment of or supplement to the prospectus as required by the Securities Act and other documents, and such other documents as the Holders may reasonably request in
order to facilitate their disposition of their Registrable Securities; 
 (d) Use its reasonable best efforts to register and
qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be required in connection
therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions unless the Company is already subject to service in such jurisdiction and except as may be required
by the Securities Act; 
 (e) Notify each seller of Registrable Securities covered by such registration statement at any time
when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification promptly prepare and
furnish to such Holder a reasonable number of copies of a 

  
 9 

 
supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; 

(f) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (g) Cause
all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; 
 (h) Otherwise use its commercially reasonable efforts to comply with all applicable rules and regulations of the Commission; 
 (i) In connection with any underwritten offering, pursuant to a registration statement filed pursuant to Section 2.1 hereof, enter into an underwriting agreement in form reasonably necessary to
effect the offer and sale of Common Stock, provided such underwriting agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such underwriting shall also enter into and
perform its obligations under such an agreement; 
 (j) Use its reasonable best efforts to furnish, at the request of any Holder
requesting registration of Registrable Securities pursuant to this Section 2, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 2, if such
securities are being sold through underwriters, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten
public offering and reasonably satisfactory to a majority-in-interest of Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities, and (ii) a letter dated such
date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a
majority-in-interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities; and 
 (k) Promptly make available for inspection by the selling Holders, any underwriter participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent
retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent
accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent in connection with any such registration statement. 

  
 10 

 2.6 Indemnification. 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, each of its officers, directors,
stockholders, members and partners, legal counsel, accountants and investment advisors and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification, or
compliance has been effected pursuant to this Section 2, and each underwriter, if any, and each person who controls within the meaning of Section 15 of the Securities Act any underwriter, against all expenses, claims, losses, damages, and
liabilities (or actions, proceedings, or settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus, offering
circular, or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification, or compliance; (ii) any omission (or alleged omission) to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading; or (iii) any violation (or alleged violation) by the Company of the Securities Act, the Exchange Act, any state securities laws or any rule or regulation
thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any offering covered by such registration, qualification, or compliance, and the Company will reimburse each such Holder, each of its
officers, directors, stockholders, members, partners, legal counsel, accountants and investment advisors and each person controlling such Holder, each such underwriter, and each person who controls any such underwriter, for any legal and any other
expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage, liability, or action as they are incurred; provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished to the Company and stated to be specifically for use therein by such Holder, any of such
Holder’s officers, directors, partners, legal counsel, accountants or investment advisors, any person controlling such Holder, such underwriter or any person who controls any such underwriter; and provided further that, the
indemnity agreement contained in this Section 2.6(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such settlement is effected without the consent of the Company (which consent shall not
be unreasonably withheld or delayed). 
 (b) To the extent permitted by law, each selling Holder will, if Registrable Securities
held by such Holder are included in the securities as to which such registration, qualification, or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel, and accountants and
each underwriter, if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other selling Holder, and
each of their officers, directors, stockholders, members and partners, and each person controlling each other selling Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on:
(i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any such registration statement, prospectus, offering circular, or other document, or (ii) any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and such Holder will reimburse the Company and other selling Holders, directors, officers, stockholders, members,
partners, legal counsel, and accountants, persons, underwriters, or control persons for any legal or any other expenses 

  
 11 

 
reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability, or, action as they are incurred, in each case to the extent, but only to the extent,
that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular, or other document in reliance upon and in conformity with written information furnished
to the Company by such Holder and stated to be specifically for use therein; provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages, or
liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which consent shall not be unreasonably withheld); and provided, further, that in no event shall any indemnity under this
Section 2.6 exceed the net proceeds from the offering received by such Holder. 
 (c) Each party entitled to
indemnification under this Section 2.6 (the “Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual
knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall conduct
the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party’s expense;
provided, further, however, that an Indemnified Party (together with all other Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and
expenses to be paid by the Indemnifying Party, if representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be inappropriate due to actual or potential differing interests between such Indemnified Party and any
other party represented by such counsel in such proceeding; and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this
Section 2.6, to the extent such failure is not materially prejudicial to the Indemnifying Party’s ability to defend such action. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each
Indemnified Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to
such claim or litigation. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of
such claim and litigation resulting therefrom. 
 (d) If the indemnification provided for in this Section 2.6 is held by a
court of competent jurisdiction to be unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall
contribute to the amount paid or payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the
Indemnified Party on the other in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations; provided, however, that no
contribution by any Holder, when combined with any amounts paid by such Holder pursuant to Section 2.6(b), shall exceed the net proceeds from the 

  
 12 

 
offering received by such Holder. The relative fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information, and
opportunity to correct or prevent such statement or omission. 
 (e) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall
control. 
 (f) The obligations of the Company and Holders under this Section 2.6 shall survive the completion of any
offering of Registrable Securities in a registration statement, and otherwise. 
 2.7 Information by Holder. Each Holder
of Registrable Securities shall furnish to the Company such information regarding such Holder and the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any
registration, qualification, or compliance referred to in this Section 2. 
 2.8 Restrictions on Transfer.

 (a) The Holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects
with the provisions of this Section 2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until
(x) the transferee thereof has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by, the terms and conditions set forth in this Agreement, including, without limitation,
this Section 2.8 and Section 2.10, and (y): 
 (i) There is then in effect a registration statement
under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 
 (ii) Such Holder shall have given prior written notice to the Company of such Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the
manner and circumstances of the proposed disposition, and, if requested by the Company, such Holder shall have furnished the Company, at such Holder’s expense, with (A) an opinion of counsel, reasonably satisfactory to the Company, to the
effect that such disposition will not require registration of such Restricted Securities under the Securities Act or (B) a “no action” letter from the Commission to the effect that the transfer of such securities without registration
will not result in a recommendation by the staff of the Commission that action taken with respect thereto, whereupon the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms of
the notice delivered by the Holder to the Company. It is agreed that the Company will not require opinions of counsel or “no action” letters for transactions made pursuant to Rule 144, except in unusual circumstances, or as permitted under
Section 2.8(c)(iii). 

  
 13 

 (iii) Notwithstanding the provisions of subsections (a)(i) and (a)(ii)
above, no such registration statement or opinion of counsel or “no action” letter shall be necessary for: (A) a transfer by a Holder to any of its affiliates (including, for the purposes of this Agreement and the avoidance of doubt,
subsidiaries and parent companies of the Holder, and including an affiliated fund managed by the same manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such
manager or managing member or general partner or management company, each an “Affiliated Fund”) or any other Person that shares a common investment advisor with such Holder; (B) a transfer by a Holder that is a partnership,
limited liability company or corporation to a partner, limited partner, retired partner, member, retired member or stockholder of a Holder; (C) a transfer by gift, will or intestate succession of any partner to his or her spouse or to the
siblings, lineal descendants or ancestors of such partner or his or her spouse; or (D) the transfer, by a Holder exercising its co-sale rights under the Right of First Refusal and Co-Sale Agreement by and among the Company and the Investors and
certain other stockholders named therein, dated as of September 10, 2012, as it may be amended and/or restated from time to time (the “ROFR Agreement”), if in each transfer under clauses (A), (B) or (C), the prospective
transferee agrees in all such instances in writing to be subject to the terms hereof to the same extent as if he or she were an original Holder hereunder. 
 (b) Each certificate representing Registrable Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped or otherwise imprinted with a legend substantially similar to the
following (in addition to any legend required under applicable state securities laws): 
 THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE
OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 

  
 14 

 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON
TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD OF UP TO 180 DAYS (SUBJECT TO EXTENSION) IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTOR RIGHTS AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.

 The Holders consent to the Company making a notation on its records and giving instructions to any transfer agent of the
Restricted Securities in order to implement the restrictions on transfer established in this Section 2.8. 
 (c) The first
legend referring to federal and state securities laws identified in Section 2.8(b) hereof stamped on a certificate evidencing the Restricted Securities and the stock transfer instructions and record notations with respect to such Restricted
Securities shall be removed and the Company shall issue a certificate without such legend to the holder of such Restricted Securities if: (i) such securities are registered under the Securities Act; (ii) such holder provides the Company
with an opinion of counsel reasonably acceptable to the Company to the effect that a public sale or transfer of such securities may be made without registration under the Securities Act; or (iii) such holder provides the Company with reasonable
assurances, which may, at the option of the Company, include an opinion of counsel reasonably satisfactory to the Company, that such securities can be sold pursuant to Rule 144 under the Securities Act. 

2.9 Rule 144 Reporting. With a view to making available the benefits of certain rules and regulations of the Commission that may
permit the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: 
 (a) Make and keep public information regarding the Company available as those terms are understood and defined in Rule 144 under the Securities Act, at all times from and after the effective date of the
first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 
 (b)
File with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and 

(c) So long as a Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following the effective date of the first registration statement filed by the Company for an offering of its securities to the
general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so
filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 

  
 15 

 2.10 Market Stand-Off Agreement. If requested by the Company and the managing
underwriter of Common Stock (or other securities) of the Company, each Holder hereby agrees that such Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar
transaction with the same economic effect as a sale, of any Common Stock (or other securities) of the Company held by such Holder immediately prior to the effective date for the registration statement for the Initial Public Offering (other than any
shares included in the registration) during one hundred and eighty (180) day period following the effective date of the Initial Public Offering or, if requested by such managing underwriter, such longer period of time as is necessary for
compliance with rules of the Financial Industry Regulatory Authority, provided, however, that such extension shall not exceed thirty-four (34) days following the expiration of the original one hundred and eighty (180) day
period; provided, further, that such restriction shall not apply to a transfer by a Holder to its affiliate (including an Affiliated Fund) or any Person that shares a common investment advisor with such Holder if such transferee agrees
to be bound by the provisions hereof in the same manner as such transferring Holder. The foregoing provisions of this Section 2.10 shall be applicable to the Holders only if all officers, directors, and stockholders individually owning
more than one percent (1%) of the outstanding Common Stock are subject to the same restrictions and provided, in addition, the Company will use commercially reasonable efforts to obtain the consent of the managing underwriter for earlier
release of market stand-off and transfer restrictions on a portion of the Holders’ Common Stock and if the Company or any underwriter of the Initial Public Offering waives or terminates any market stand-off or transfer restrictions imposed on
any holder of securities of the Company, then such waiver or termination shall be granted to all Holders subject to market stand-off or transfer restrictions hereby, pro rata based on the number of shares of Common Stock beneficially held by such
other holder and the Holders hereby. The Company may impose stop-transfer instructions and may stamp each such certificate with the second legend set forth in Section 2.8(b) hereof with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day period. Each Holder agrees to execute a market standoff agreement with said underwriters in customary form consistent with the provisions of
this Section 2.10. 
 2.11 Delay of Registration. No Holder shall have any right to take any action to restrain,
enjoin, or otherwise delay any registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 
 2.12 Transfer or Assignment of Registration Rights. The rights to cause the Company to register securities granted to a Holder by the Company under this Section 2 may be transferred or
assigned by a Holder only to: (a) a transferee or assignee who acquires at least five percent (5%) of the Investor’s shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits,
stock dividends, reverse stock splits, and the like); (b) an affiliate of a Holder (including an Affiliated Fund) or any other Person that shares a common investment advisor with such Holder or a subsidiary, parent, partner, limited partner,
retired partner, member, retired member or stockholder of a Holder; or (c) a Holder’s family member or trust for the benefit of an individual Holder or Holder’s family member; provided that (i) any such transfer or assignment of
Registrable Securities is effected in accordance with the terms of Section 2.8 hereof, and applicable securities laws; (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address of the
transferee or assignee and identifying the securities with respect to which such registration rights are intended to be transferred or assigned; (iii) the transferee or assignee of such rights assumes in writing the obligations of such Holder
under this Agreement, including without limitation the obligations set forth in Section 2.10; and (iv) any such transferee is not engaged in competition with the Company as reasonably determined by the Board of Directors. 

  
 16 

 2.13 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Holders of at least two-thirds of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company giving such
holder or prospective holder any registration rights if (a) such registration rights would be pari passu with, or senior to, any registration rights provided under this Agreement or (b) such holder or prospective holder would not be bound
by obligations similar to the obligations of the Holders set forth in Sections 2.4 (regarding forfeiture of rights), 2.6, 2.7, 2.10 and 2.11. 
 2.14 Termination of Registration Rights. The right of any Holder to request registration or inclusion in any registration pursuant to Section 2.1, 2.2 or 2.3 shall terminate on the earlier of
(i) the date on which the Holder or any permitted transferee of a Holder owns no Registrable Securities and (ii) five (5) years after the closing of the Company’s Initial Public Offering. 

SECTION 3 
 COVENANTS OF THE COMPANY 
 The Company hereby covenants and agrees,
as follows: 
 3.1 Basic Financial Information. Provided that any shares of Preferred Stock or Registrable Securities
remain outstanding, the Company shall deliver to each Investor the following financial information: 
 (a) as soon as
practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the
end of such year, and a statement of cash flows for such year, plus, where applicable, comparisons to the annual budget and operating plan approved by the Board of Directors; such year-end financial reports to be in reasonable detail, prepared in
accordance with generally accepted accounting principles in the United States (“GAAP”), and audited and certified by an independent public accounting firm of nationally or regionally recognized standing selected by the Board of
Directors or a committee thereof; 
 (b) as soon as practicable, but in any event within thirty (30) days after the end of
each of the four quarters of each fiscal year of the Company, an unaudited profit or loss statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, plus, where applicable,
quarterly comparisons to the annual budget and operating plan approved by the Board of Directors; such unaudited financial statements to be prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the
exception of footnotes that may be required by GAAP) and that fairly present the financial condition of the Company and its results of operations for the period specified, subject to year-end audit adjustment; 

  
 17 

 (c) as soon as practicable, but in any event within thirty (30) days of the end of each
month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, plus, where applicable, monthly comparisons to the annual budget
and operating plan approved by the Board of Directors; such unaudited financial statements to be prepared in accordance with GAAP and fairly present the financial condition of the Company and its results of operation for the period specified,
subject to year-end audit adjustment; 
 (d) as soon as practicable, but in any event within thirty (30) days prior to the
commencement of each new fiscal year of the Company, an annual budget and operating plan for such fiscal year as approved by the Board of Directors; 
 (e) as soon as practicable, but in any event within fifteen (15) days of the end of each fiscal quarter, an updated capitalization table, certified by the Treasurer of the Company; and 

(f) such other information as may be reasonably requested by an Investor from time to time, provided, however, that the Company
shall not be obligated under this Section 3.1(f) to provide information that the Company reasonably determines in good faith to be a trade secret or highly confidential proprietary information (unless the provision of such information to
such Investor is covered by a separate enforceable confidentiality agreement with such Investor, in form reasonably acceptable to the Company). 
 3.2 Inspection Rights. Provided that any of the Preferred Stock originally issued by the Company or the Registrable Securities remain outstanding, the Company will afford to each Investor
reasonable access during normal business hours to all of the Company’s properties, books and records. Investors may exercise their rights under this Section 3.2 only for purposes reasonably related to their interests as a stockholder. The
rights granted pursuant to Section 3.1 and this Section 3.2 may be assigned or otherwise conveyed by any Investor to any person that is a transferee of an Investor’s shares, which transferee is either (i) an Affiliated Fund of
such Investor, (ii) an affiliate, (iii) any Person that shares a common investment advisor with such Investor or (iv) holds at least twenty percent (20%) of the outstanding shares of Preferred Stock (on an as-converted into
Common Stock basis), and such transferee shall be deemed to be an Investor for purposes of Sections 3.1 and 3.2 hereof, unless such transferee is reasonably deemed by the Company to be a competitor of the Company. 

3.3 Confidentiality. The Company shall not be required to comply with Sections 3.1 or 3.2 in respect of any Holder whom the
Company reasonably determines to be (a) a Competitor or (b) an officer, employee, director or holder of more than ten percent (10%) of a Competitor, nor shall the Company be obligated to disclose any information which the Board of
Directors determines in good faith is attorney-client privileged and should not, therefore, be disclosed. A “Competitor” means any person or entity engaged, directly or indirectly (including through any partnership, limited
liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the Company’s business, but shall not include (i) any financial investment firm or collective investment vehicle solely by
virtue of its ownership (and/or its affiliates’ ownership) of an equity interest in any Competitor solely for investment purposes, (ii) Google Ventures 2011, L.P. or any of its affiliated venture capital funds solely as a 

  
 18 

 
result of any affiliation between such Holder and Google Inc., (iii) Laboratory Corporation of America Holdings or any of its affiliates (collectively, “LabCorp”), or
(iv) Roche Finance Ltd or any of its affiliates (collectively, “Roche”). Each Holder agrees that it will not use any information received by it pursuant to this Agreement in violation of the Exchange Act or reproduce, disclose
or disseminate such information to any other person other than its employees, officers, directors, agents, partners or investment advisors having a need to know the contents of such information, and its attorneys, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; and to any prospective purchaser of any Registrable Securities from such Holder, if such prospective purchaser agrees to be
bound by the provisions of this Section 3.3 or as may otherwise be required by law, provided that the Holder promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required
disclosure; provided, further, however, that the restrictions set forth above in this sentence shall not apply to any information that, with respect to such Holder, (a) is known or becomes known to the public in general (other than as a result
of a breach of this Section 3.3 by such Holder), (b) is or has been independently developed or conceived by the Holder without use of the Company’s confidential information, or (c) is or has been made known or disclosed to
the Holder by a third party without a breach of any obligation of confidentiality such third party may have to the Company. The Company acknowledges that certain of the Investors and/or their investment advisors are in the business of venture
capital and other types of investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises that may have products or services that compete directly or indirectly with those of the
Company. Nothing in this Agreement shall preclude or in any way restrict the Investors or their investment advisors from investing or participating in any particular enterprise, regardless of whether such enterprise has products or services that
compete with those of the Company. In addition, the Company acknowledges that LabCorp is in the business of providing various laboratory products and services and may provide products or services that compete directly or indirectly with those of the
Company. In addition, the Company acknowledges that Roche are in the diagnostic and pharmaceutical business globally and accordingly may research, develop and/or market products, devices or services that compete directly or indirectly with those of
the Company. Nothing in this Agreement shall preclude or in any way restrict LabCorp or Roche from researching, developing or marketing products, devices or services that compete, directly or indirectly, with those of the Company or investing or
participating in any particular enterprise, regardless of whether such enterprise has products or services that compete with those of the Company. 
 3.4 Vesting. Unless otherwise approved by Super Board Approval, or the holders of at least two-thirds of the then outstanding shares of Preferred Stock (on an as-converted to Common Stock basis),
all option and capital stock grants to employees, directors and consultants of the Company made after the date of this Agreement shall vest no faster than over a four (4) year period, with twenty-five percent (25%) of the shares subject to
each grant vesting one (1) year after the vesting commencement date and the remainder of the shares vesting in equal amounts on a quarterly basis thereafter. 
 3.5 D&O Insurance. The Company shall maintain Director and Officer liability insurance in an amount approved by the Board of Directors. 

  
 19 

 3.6 Certain Approval Requirements. The Company hereby covenants and agrees with each
of the Investors that it shall not, by amendment, merger, consolidation or otherwise, take any of the following actions or obligate the Company or any subsidiary to take any of the following actions without Super Board Approval: 

(a) Make any investment other than investments in prime commercial paper, money market funds, certificates of deposit in any United States
bank having a net worth in excess of $100,000,000 or obligations issued or guaranteed by the United States of America, in each case having a maturity not in excess of one (1) year; 

(b) Hire, terminate or change the compensation of senior managers (including the payment of bonuses or other non-salary payments to
senior managers of the Company) in a manner that is not authorized in the Company’s annual budget and operating plan (delivered to the Investors in accordance with 3.1(d) hereof) or by written employment agreements with such senior managers
that have previously been approved by the Board of Directors and furnished to the Investors in connection with the sale of the Shares pursuant to the Purchase Agreement; 
 (c) Adopt, amend or terminate any stock option or other equity incentive plan; 

(d) Effect, or cause any subsidiary or affiliate of the Company to effect, any acquisition of another company or entity by stock
purchase, merger or otherwise or acquire all or substantially all of the assets of another company or entity; 
 (e) Incur or
permit any subsidiary or affiliate of the Company to incur aggregate indebtedness in excess of $100,000 other than (i) as authorized in the Company’s annual budget and operating plan (delivered to the Investors in accordance with 3.1(d)
hereof) or (ii) trade credit incurred in the ordinary course of business; 
 (f) Make, or permit any subsidiary to make,
any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 
 (g) Make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar
expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors, which approval contained at least two (2) of the Preferred Stock Directors; 

(h) Guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (i) Enter into or be a party to any
transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person; or 

(j) Approve the annual budget and operating plan of the Company. 

  
 20 

 3.7 Non-Disclosure, Assignment of Inventions and Non-Competition and Non-Solicitation
Agreements. The Company shall obtain, and shall cause its subsidiaries (if any) to obtain, a confidentiality and assignments of inventions agreement from all employees, consultants and scientific advisory board (“SAB”) members
in a form approved by Super Board Approval. In addition, the agreement for employees and consultants shall, to the full extent permitted by law, contain one-year post-termination non-competition and non-solicitation provisions in a form approved by
Super Board Approval. In the case of consultants and SAB members, such agreements shall be subject to the policies of any academic or research institutions with which such consultant or SAB member is affiliated. 

3.8 Termination of Covenants. The covenants set forth in this Section 3 shall terminate and be of no further force or effect
after the closing of a Qualified Public Offering. 
 SECTION 4 

RIGHT OF FIRST REFUSAL 
 4.1 Right of Refusal of the Investors. 
 (a) Provided that any of the
Preferred Stock originally issued by the Company or any of the Registrable Securities remain outstanding, the Company hereby grants to each Investor a right of first refusal to purchase its Pro Rata Share (as defined below) of New Securities (as
defined in Section 4.1(b)) which the Company may, from time to time, propose to sell and issue after the date of this Agreement. An Investor’s “Pro Rata Share” is equal to the ratio of (i) the number of shares of Common
Stock then owned by such Investor (assuming full conversion of the Shares into Common Stock and exercise and conversion of all outstanding convertible securities, rights, options and warrants, directly or indirectly, into Common Stock held by such
Investor) to (ii) the total number of shares of Common Stock then owned by all stockholders of the Company immediately prior to issuance of the New Securities (assuming full conversion of the Shares and exercise or conversion of all outstanding
convertible securities, rights, options and warrants, directly or indirectly into Common Stock held by such stockholder, but excluding (x) outstanding options under any Company stock plan and (y) any shares of Common Stock issued
from and after the date hereof upon the exercise of options under any Company stock plan). For purposes of this Section 4.1, an Investor includes any general partner, managing member and affiliates (including Affiliated Funds) of an Investor.
An Investor who chooses to exercise its right of first refusal may designate as purchasers under such right itself and/or its partners, affiliates (including Affiliated Funds) or any other Persons that share a common investment advisor with such
Investor, in such proportions as it deems appropriate. 
 (b) “New Securities” shall mean any capital stock
(including Common Stock and/or Preferred Stock) of the Company whether now authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any type whatsoever that are, or may become,
exercisable or convertible into capital stock; provided that the term “New Securities” does not include: 
 (i) the Shares and the Conversion Stock; or 
 (ii) Exempted
Securities (as defined in the Restated Certificate). 

  
 21 

 (c) In the event the Company proposes to undertake an issuance of New Securities, it shall
give each Investor written notice of its intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes to issue the same. Each Investor shall have twenty (20) days after any such notice
is mailed or delivered to agree to purchase such Holder’s Pro Rata Share of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and stating therein the quantity of New Securities
to be purchased. If any Investor fails to so agree in writing within such twenty (20) day period to purchase such Holder’s full Pro Rata Share of an offering of New Securities (a “Nonpurchasing Holder”), then such
Nonpurchasing Holder shall forfeit the right hereunder to purchase that part of such Nonpurchasing Holder’s Pro Rata Share of such New Securities that such Nonpurchasing Holder did not so agree to purchase. The Company shall promptly give each
Investor who has timely agreed to purchase such Holder’s full Pro Rata Share of such offering of New Securities (a “Purchasing Holder”) written notice of the failure of any Nonpurchasing Holder to purchase such Nonpurchasing
Holder’s full Pro Rata Share of such offering of New Securities (the “Overallotment Notice”). Each Purchasing Holder shall have a right of overallotment such that such Purchasing Holder may agree to purchase a portion of the
Nonpurchasing Holders’ unpurchased pro rata portion of such offering on a pro rata basis according to the relative pro rata portion of the Purchasing Holders, at any time within five (5) days after receiving the Overallotment Notice.

 (d) In the event the Investors fail to exercise fully the right of first refusal within said twenty (20) day period plus
five (5) days (the “Election Period”), the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within
ninety (90) days from the date of said agreement) to sell to any Person or Persons any or all New Securities which have not been subscribed by Investors pursuant to their right of first refusal option set forth in this Section 4.1. Any
such sale to such Person or Persons shall be at a price and upon terms no more favorable to the purchasers thereof than specified in the Company’s notice to Investors delivered pursuant to Section 4.1(c). In the event the Company has not
sold such unsubscribed New Securities within such ninety (90) day period following the Election Period, or such ninety (90) day period following the date of said agreement, the Company shall not thereafter issue or sell such New Securities
without first again offering such New Securities to the Investors in the Manner provided in this Section 4.1. 
 (e) The
rights of an Investor to purchase New Securities under this Section 4.1 may be waived in accordance with Section 5.2 hereof; provided, however, in the event that the rights of an Investor to purchase New Securities under this
Section 4.1 are waived in a particular offering without such Investor’s prior written consent (any such Investor, a “Waived Investor”) and any other Investor actually purchases New Securities in such offering, then the
Company shall grant, and hereby grants, each Waived Investor the right to receive reasonable notice of, and to purchase a portion of the New Securities offered in such offering equal to its Pro Rata Share in, a subsequent closing of such offering
which shall be held within twenty (20) days following, and on the same terms and conditions as, such other Investor(s) actual purchase. For clarity, if a Waived Investor does not elect to participate in such subsequent closing of such offering,
then such Waived Investor shall not have a second right to participate in such offering solely because another Waived Investor actually exercises its right to participate in such subsequent closing of such offering. 

  
 22 

 (f) The right of first refusal granted under Section 4.1 shall not be applicable to an
Initial Public Offering and shall terminate immediately prior to the closing thereof. 
 SECTION 5 

MISCELLANEOUS 
 5.1 Additional investors; Permitted Transferees. Notwithstanding anything to the contrary herein, if the Company shall issue additional shares of its Preferred Stock or if an Investor engages in
any of the following permitted transfers: (A) a transfer by an Investor to any of its affiliates (including an Affiliated Fund) or any other Person that shares a common investment advisor with such Investor; (B) a transfer by an Investor
that is a partnership, limited liability company or corporation to a partner, limited partner, retired partner, member, retired member or stockholder of an Investor; (C) a transfer by gift, will or intestate succession of any partner to his or
her spouse or to the siblings, lineal descendants or ancestors of such partner or his or her spouse; or (D) the transfer by an Investor exercising its co-sale rights under the ROFR Agreement, then in the event of a transfer under clauses (A),
(B) or (C), any purchaser or permitted transferee of such shares of Preferred Stock may become a party to this Agreement by executing and delivering an adoption agreement to this Agreement, in the form of Attachment A (the
“Adoption Agreement”) and shall be deemed an “Investor” hereunder and Schedule A shall be amended to include such Investor or permitted transferee. 

5.2 Amendment; Waiver. Except as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived,
discharged or terminated other than by a written instrument referencing this Agreement and signed by the Company and the Holders of at least two-thirds of the then outstanding Registrable Securities. Any such amendment, waiver, discharge or
termination effected in accordance with this paragraph shall be binding upon each Holder and each future holder of all such securities of the Holder. Each Holder acknowledges that by the operation of this paragraph, the Holders of at least
two-thirds of the then outstanding Registrable Securities will have the right and power to diminish or eliminate all rights of such Holder under this Agreement, including rights under Section 4.1 hereof other than such Holder’s rights
under Section 4.1(a) hereof in relation to a particular offering. Notwithstanding the foregoing, this Agreement may not be amended, modified or terminated and the observance of any term hereunder may not be waived with respect to any Holder
without the written consent of such Holder unless such amendment, modification, termination or waiver applies to all Holders in the same fashion (it being agreed that, subject to Section 4.1(e) hereof, a waiver of the provisions of
Section 4.1 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the
Company, purchase securities in such transaction). Any provision and/or the observance thereof may be waived by the individual or entity entitled to the benefits of such provision. 

  
 23 

 5.3 Notices. All notices and other communications required or permitted hereunder
shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail or otherwise delivered by hand or by messenger addressed: 

(a) if to an Investor one copy should be sent to the Investor, at the Investor’s address, facsimile number or electronic mail address
as shown in the Company’s records, as may be updated in accordance with the provisions hereof, with a copy to (i) Greenberg Traurig, LLP, One International Place, Boston, MA 02110, Attn: Bradley A. Jacobson, Esq., facsimile:
(617) 279-8402, (ii) Faber Daeufer Itrato & Cabot, 950 Winter Street, Suite 4500, Waltham, MA 02451, Attn: Joseph L. Faber, Esq., facsimile: (781) 795-4747, and (iii) K&L Gates LLP, 4350 Lassiter at North Hills
Avenue, Suite 300, PO Box 17047, Raleigh, North Carolina 27619, Attn: D. Scott Coward, Esq., facsimile: (919) 516-2028; 

(b) if to any Holder, at such address, facsimile number or electronic mail address as shown in the Company’s records, or, until any
such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to and at the address of the last Holder of such shares for which the Company has contact information in its records; or 

(c) if to the Company, one copy should be sent to c/o Foundation Medicine, Inc., One Kendall Square, Suite B3501 Cambridge MA 02139,
Attn: Chief Executive Officer, or at such other address as the Company shall have furnished to the Investors, with a copy to Goodwin Procter LLP, Exchange Place, Boston, MA 02109, Attn: Kingsley L. Taft, Esq., facsimile: (617) 523-1231.

 Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given
when delivered if delivered personally, or, if sent by mail or commercial overnight delivery service, at the earlier of its receipt or seventy-two (72) hours after the same has been deposited in a regularly maintained receptacle for the deposit
of the United States mail or with such commercial overnight delivery service, addressed and mailed as aforesaid or, if sent by facsimile, upon confirmation of facsimile transfer or, if sent by electronic mail, upon confirmation of delivery when
directed to the electronic mail address set forth on the Schedule of Investors. Each such notice or other communication sent outside the United States shall be sent by commercial overnight delivery service. 

5.4 Governing Law. This Agreement shall be governed by and construed in accordance with the General Corporation Law of the State
of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws.

 5.5 Successors and Assigns. Except as otherwise provided herein, the provisions of this Agreement shall inure to the
benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 
 5.6
Entire Agreement. This Agreement and the Schedules hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and supersedes all prior written or oral agreements and understandings
relating to such subject 

  
 24 

 
matter. No party hereto shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as
specifically set forth herein. By executing this Agreement, the undersigned Investors who are also parties to the Prior Agreement, representing the Holders of at least two-thirds of the Registrable Securities outstanding on the date hereof, hereby
amend and restate the Prior Agreement in its entirety as set forth in this Agreement. 
 5.7 Delays or Omissions. Except
as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right, power or remedy of such
non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed
a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any
party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to
this Agreement, shall be cumulative and not alternative. 
 5.8 Severability. If any provision of this Agreement becomes
or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and such court will replace such
illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable provision. The balance
of this Agreement shall be enforceable in accordance with its terms. 
 5.9 Titles and Subtitles. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and schedules shall, unless otherwise provided, refer
to sections and paragraphs hereof and schedules attached hereto. 
 5.10 Counterparts. This Agreement may be executed in
any number of counterparts, each of which shall be enforceable against the parties that execute such counterparts, and all of which together shall constitute one instrument. 
 5.11 Telecopy Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties hereto and delivered by such party by facsimile or any
similar electronic transmission device pursuant to which the signature of or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes. At the request of any party hereto, all
parties hereto agree to execute and deliver an original of this Agreement as well as any facsimile, telecopy or other reproduction hereof. 

  
 25 

 5.12 Further Assurances. Each party hereto agrees to execute and deliver, by the
proper exercise of its corporate, limited liability company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things as may be necessary to more fully effectuate this Agreement.

 5.13 Aggregation of Stock. All shares of Registrable Securities held or acquired by affiliated entities or persons or
entities under common investment management or control shall be aggregated together for the purpose of determining the availability of any rights or obligations under this Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 26 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amended and Restated
Investors’ Rights Agreement effective as of the date first written above. 
  

			
	COMPANY:
	
	FOUNDATION MEDICINE, INC.
		
	By:	 	/s/ Michael Pellini, M.D.
	Name:	 	Michael Pellini, M.D.
	Title:	 	President and Chief Executive Officer

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	THIRD ROCK VENTURES, L.P.
		
	By:	 	Third Rock Ventures GP, L.P., its general partner
		
	By:	 	TRV GP, LLC, its general partner
		
	By:	 	/s/ Kevin Gillis
	Name:	 	Kevin Gillis
	Title:	 	CFO/Partner

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	GOOGLE VENTURES 2011, L.P.
		
	By:	 	Google Ventures 2011 GP, L.L.C., its general partner
		
	By:	 	/s/ William J. Maris
	Name:	 	William J. Maris 
	Title:	 	Member

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	KPCB HOLDINGS, INC., AS NOMINEE
		
	By:	 	/s/ Paul Vronsky
	Name:	 	Paul Vronsky
	Title:	 	General Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	LABORATORY CORPORATION OF AMERICA HOLDINGS 
		
	By:	 	/s/ Adam Feinstein
	Name:	 	Adam Feinstein
	Title:	 	SVP, Corp. Development & Strategy

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	ROCHE FINANCE LTD
		
	By:	 	/s/ Andreas Knierzinger
	Name:	 	Andreas Knierzinger
	Title:	 	Authorized Signatory
		
	By:	 	/s/ Carole Nuechterlein
	Name:	 	Carole Nuechterlein
	Title:	 	Authorized Signatory

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	HAWKES BAY MASTER INVESTORS (CAYMAN) LP
		
	By:	 	Wellington Management Company, LLP, as investment advisor
		
	By:	 	/s/ Steven M. Hoffman
	Name:	 	Steven M. Hoffman
	Title:	 	Vice President and Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	QUISSETT INVESTORS (BERMUDA) L.P.
		
	By:	 	Wellington Management Company, LLP, as investment advisor
		
	By:	 	/s/ Steven M. Hoffman
	Name:	 	Steven M. Hoffman
	Title:	 	Vice President and Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	QUISSETT PARTNERS, L.P.
		
	By:	 	Wellington Management Company, LLP, as investment advisor
		
	By:	 	/s/ Steven M. Hoffman
	Name:	 	Steven M. Hoffman
	Title:	 	Vice President and Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	SALTHILL INVESTORS (BERMUDA) L.P.
		
	By:	 	Wellington Management Company, LLP, as investment advisor
		
	By:	 	/s/ Steven M. Hoffman
	Name:	 	Steven M. Hoffman
	Title:	 	Vice President and Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	SALTHILL PARTNERS, L.P.
		
	By:	 	Wellington Management Company, LLP, as investment advisor
		
	By:	 	/s/ Steven M. Hoffman
	Name:	 	Steven M. Hoffman
	Title:	 	Vice President and Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	WUXI PHARMATECH HEALTHCARE FUND I, L.P.
		
	By:	 	Wuxi PharmaTech Fund I General Partner L.P., its general partner
		
	By:	 	WuXi PharmaTech Investments (Cayman) Inc., its general partner
		
	By:	 	/s/ Ge Li
	Name:	 	Ge Li
	Title:	 	Director

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
		
	By:	 	Deerfield Mgmt, L.P., its general partner
		
	By:	 	J. E. Flynn Capital, LLC, its general partner
		
	By:	 	/s/ David J. Clark
	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
		
	By:	 	Deerfield Mgmt, L.P., its general partner
		
	By:	 	J. E. Flynn Capital, LLC, its general partner
		
	By:	 	/s/ David J. Clark
	Name:	 	David J. Clark
	Title:	 	Authorized Signatory

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	CASDIN PARTNERS MASTER FUND, LP
		
	By:	 	Casdin Partners GP, LLC, its general partner
		
	By:	 	/s/ Eli Casdin
	Name:	 	Eli Casdin
	Title:	 	Managing Member

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	LEERINK SWANN HOLDINGS, LLC
		
	By:	 	/s/ Timothy A.G. Gerhold
	Name:	 	Timothy A.G. Gerhold
	Title:	 	General Counsel

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	LEERINK SWANN CO-INVESTMENT FUND, LLC
		
	By:	 	/s/ Jeffrey Leerink
	Name:	 	Jeffrey Leerink
	Title:	 	Manager

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	 INVESTORS:
  

REDMILE CAPITAL OFFSHORE FUND II, LTD.

		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title:   Managing Member of the Investment Manager

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	 INVESTORS:
  

REDMILE SPECIAL OPPORTUNITIES FUND, LTD.

		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title:   Managing Member of the Investment Manager

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	 INVESTORS:
  

REDMILE VENTURES, LLC

		
	By:	 	/s/ Jeremy Green
	Name: Jeremy Green
	Title:   Managing Member of the Investment Manager

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	 INVESTORS:
  

DAVID P. SCHENKEIN 2004 REVOCABLE TRUST

		
	By:  	 	/s/ David Schenkein
		 	David Schenkein, Trustee

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	AMY P. SCHENKEIN 2004 REVOCABLE TRUST
		
	By:	 	/s/ Amy P. Schenkein
		 	Amy P. Schenkein, Trustee

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	LIGHTHOUSE CAPITAL PARTNERS VI, L.P.
	
	
	By:	 	Lighthouse Management Partners VI, L.L.C.,
		 	its general partner

  

			
	By:	 	/s/ Cristy Barnes
	Name:	 	Cristy Barnes
	Title:	 	Managing Director

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	APOLETTO LIMITED
		
	By:	 	/s/ Sara Hollinrake
	Name:	 	Sara Hollinrake
	Title:	 	Director

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	JVEN CAPITAL, LLC
		
	By:	 	/s/ Evan Jones
	Name:	 	Evan Jones
	Title:	 	Managing Member

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 
			
	INVESTORS:
	
	GATES VENTURES, LLC
		
	By:	 	/s/ Alan Heuberger
	Name:	 	Alan Heuberger
	Title:	 	Authorized Representative

  
 ***Signature
Page – Second Amended and Restated Investors’ Rights Agreement*** 

 SCHEDULE A 

Schedule of Investors 

Names and Addresses: 
  

	
	 Third Rock Ventures, L.P.

	
	 KPCB Holdings, Inc.

	
	 Google Ventures 2011, L.P.

	
	 Laboratory Corporation of America Holdings

	
	 Roche Finance Ltd

	
	 Hawkes Bay Master Investors (Cayman) LP

	
	 Quissett Investors (Bermuda) L.P.

	
	 Quissett Partners, L.P.

	
	 Salthill Investors (Bermuda) L.P.

	
	 Salthill Partners, L.P.

	
	 WuXi Pharmatech Healthcare Fund I, L.P.

	
	 Deerfield Special Situations Fund, L.P.

	
	 Deerfield Special Situations International Master Fund, L.P.

	
	 Casdin Partners Master Fund, LP

	
	 Leerink Swann Holdings, LLC

	
	 Leerink Swann Co-Investment Fund, LLC

	
	 Redmile Capital Offshore Fund II, Ltd.

	
	 Redmile Special Opportunities Fund, Ltd.

	
	 Redmile Ventures, LLC

	
	 David P. Schenkein 2004 Revocable Trust

	
	 Amy P. Schenkein 2004 Revocable Trust

	
	 Lighthouse Capital Partners IV, L.P.

	
	 Apoletto Limited

	
	 jVen Capital, LLC

	
	 Gates Ventures, LLC

 ATTACHMENT A 

ADOPTION AGREEMENT TO 
 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 
 This
Adoption Agreement (“Adoption Agreement”) is executed by the undersigned (the “Investor”) pursuant to the terms of that certain Second Amended and Restated Investors’ Rights Agreement dated as of June 20,
2013 (the “Agreement”) by and among Foundation Medicine, Inc. (the “Company”) and the Investors (as defined therein). Capitalized terms used but not defined herein shall have the respective meanings ascribed to such
terms in the Agreement. By the execution of this Adoption Agreement, the Investor agrees as follows: 
 1. Acknowledgment.
Investor acknowledges that Investor is acquiring certain shares of the capital stock of the Company (the “Shares”), subject to the terms and conditions of the Agreement. 

2. Agreement. Investor: (i) agrees that the Shares acquired by Investor shall be bound by and subject to the terms of the
Agreement and (ii) hereby adopts the Agreement with the same force and effect as if Investor were originally a party thereto. 
 3. Notice. Any notice required or permitted by the Agreement shall be given to Investor at the address listed beside Investor’s signature below. 

EXECUTED AND DATED this              day of
                    ,         . 

 

			
	INVESTOR:
		
	By: 	 	 
	Name:	 	
	Title:	 	

  

			
	Address: 	 	 
		 	 
	Fax:	 	 

  

			
	Accepted and Agreed:
	
	COMPANY:
	
	FOUNDATION MEDICINE, INC.
		
	By:	 	 
	Name: 	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]